Latigo prices $345.6 million IPO at $18 a share
Latigo priced its IPO at $18 a share for $345.6 million, one of the largest biotech raises of the year and enough capital to push its non-opioid painkiller against Vertex's head start. Goldman Sachs, Jefferies, Leerink and Guggenheim ran the books.